Boston Scientific Corp BSX has been in the spotlight with its acquisition of
Silk Road Medical reportedly worth US$1.16 billion. The
M&A activity stirred various reactions in the market, with the BSX stock observed to be outperforming and underperforming at intervals across different trading days. Notably, early months in 2024 delivered upbeat quarterly results, further solidifying its position. Amidst the trends, the stock reached a
52-week high and is still recommended for investment by various brokers.
Dr. Cheryl Pegus joins the Boston Scientific board, adding more depth in diverse expertise. Despite facing rising costs and competition, Boston's strength in its heart devices division led to increasing its full-year profit forecast. The company’s balance sheet reveals promising figures, with significant gains in stock recorded with several new and existing investing partners. Earnings for Q2 outperformed estimates, with a positive adjustment to the company's projected earnings. BSX has also announced the acquisition of
Axonics, Inc. and
Relievant Medsystems, Inc. The consistent performance and aggressive growth strategies, notably in M&A, positively impact BSX's standing.
Boston Scientific Corp BSX News Analytics from Tue, 19 Sep 2023 07:00:00 GMT to Sun, 23 Jun 2024 21:57:09 GMT -
Rating 6
- Innovation 8
- Information 7
- Rumor 3
